The Atossa Therapeutics (NASDAQ:ATOS) stock has started off on a rocky road this morning and has declined by 24% after the company revealed the final data from the Phase 2 clinical study of its breast cancer treatment product Endoxifen.
The patients who were part of the study were administered with the medicine in between the diagnosis of breast cancer and the eventual surgery. The most important take away from the data that was revealed was the fact that the product managed to hit its primary endpoint of reducing Ki-67.
Ki-67 is well known measure that looks into tumour activity. During the course of the window between screening and the day of the surgery, the size of the tumour was reduced by a commendable 65.1%. However, that is not all. The product also managed to meet the secondary endpoint which was related to safety and tolerability of the product. It is now going to be interesting to see if the Atossa stock manages to recover today.
Technical Indicators
| Symbol | Value | Result | Symbol | Value | Result |
| ADX | 23.7930 | Neutral | ATR14 | 0.6116 | |
| CCI20 | 225.0091 | OverBought | Chaikin Money Flow | 0.1371 | Buy |
| MACD | 0.7322 | Buy | Money Flow Index | 92.1681 | OverBought |
| ROC | 86.7692 | Buy | RSI | 89.4134 | OverBought |
| STOCH (14,3) | 80.8184 | OverBought | STOCH RSI | 1.0000 | OverBought |
| UO | 66.1447 | Buy | Williams %R | -19.1816 | OverBought |
 stock){kind=link}